HROW
Harrow Health, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$44.45-4.72%
Price as of Jul 20, 2026
HROW financials
Harrow Health, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $272.3M | $199.6M | $130.2M | $88.6M |
| Cost of revenue | $67.9M | $49.2M | $39.6M | $25.4M |
| Gross profit | $204.4M | $150.4M | $90.6M | $63.2M |
| Operating expenses | $165.8M | $141.5M | $90.1M | $61.3M |
| Operating income | $38.6M | $8.8M | $431.0K | $1.9M |
| Net income | -$5.1M | -$17.5M | -$24.4M | -$14.1M |
| EBITDA | $41.4M | $22.1M | $11.9M | -$3.9M |
| Basic EPS | $-0.14 | $-0.49 | $-0.75 | $-0.51 |
| Diluted EPS | $-0.14 | $-0.49 | $-0.75 | $-0.51 |
| Balance sheet | ||||
| Cash & equivalents | $72.9M | $47.2M | $74.1M | $96.3M |
| Total assets | $399.5M | $389.0M | $311.8M | $157.4M |
| Total liabilities | $347.4M | $319.7M | $241.8M | $130.1M |
| Stockholders’ equity | $52.4M | $69.7M | $70.4M | $27.6M |
| Total debt | $252.0M | $228.8M | $190.5M | $112.2M |
| Net debt | $179.0M | $181.6M | $116.4M | $16.0M |
| Cash flow | ||||
| Operating cash flow | $43.9M | -$22.2M | $3.8M | $1.7M |
| Capital expenditure | -$1.1M | -$38.7M | -$152.6M | -$7.8M |
| Free cash flow | $42.8M | -$60.9M | -$148.7M | -$6.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |